Drug intelligence / Profile preview

cNP5

Development stage: Preclinical
Lead developer: Neomatrix Therapeutics
Administration: Topical

Overview

cNP5 is a topical drug candidate under development by NeoMatrix Therapeutics. Its pre-Investigational New Drug (IND) work was supported by a grant from the USAMRDC. While the specific mechanism of action is not detailed in the provided context, it is being developed as a topical treatment, and its association with NeoMatrix Therapeutics' other drug candidate, NMT-cP12, suggests a potential indication for serious burn injuries.

Beyond the preview

Go deeper on cNP5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cNP5.

Explore the full profile